Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 31 - 35 of 35 results.

You searched for : August 2019 to August 2020.

Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at ...

Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer Download the PDF version of Article September 10, 2019...

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer Download the PDF version of Article September 09, 2019...

Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...

Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer Download the PDF version of...

Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions

Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions Download the PDF version of Article August 12, 2019 Basking Ridge, NJ – August 12, 2019 – Daiichi Sankyo, Inc....

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor Download the PDF version of Article August 02, 2019 TURALIO is...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...